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Available online 30 October 2014In this review, we attempt to give a concise overview of recent progress made in mechanistic understanding of
protein aggregation, particulate formation and protein solution rheology. Recent advances in analytical tech-
niques and methods for characterizing protein aggregation and the formed protein particles as well as advance-
ments, technique limitations and controversies in theﬁeld of protein solution rheology are discussed. The focus of
the review is primarily on biotherapeutics and proteins/antibodies that are relevant to that area. As per the remit
of Current Opinion in Colloid and Interface Science, here we attempt to stimulate interest in areas of debate. While
theﬁeld is certainly notmature enough that all problemsmay be considered resolved and accepted by consensus,
we wish to highlight some areas of controversy and debate that need further attention from the scientiﬁc
community.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The development of stable protein-based formulations with con-
trolled rheological response is an area of high interest for the high-
growth biotherapeutic industry, aswell as for more traditional industri-
al sectors such as foods. Although the ﬁnal applications in these two in-
dustrial sectors are very different, the complex self-assembly and
particle formation processes under various formulation conditions
(pH, ionic strength, buffer salts, temperature)must bewell-understood,
characterized, and controlled. This then allows the development of for-
mulations which remains stable with long shelf life and that exhibits
rheological properties that enhance/optimize the application perfor-
mance — e.g. processing, delivery through injection in the case of
therapeutic proteins, and texture/sensory features in the case of foods.
The early detection and characterization of protein particles or aggre-
gates — their size, structure, morphology, interactions and rheology in
therapeutic protein formulations are critical to reduce safety issues
(e.g. immunogenic response in biologics) and to ensure stability and op-
timized delivery etc. [1–4]. In food based systems, the food protein self-
assembly, microstructure and resulting rheological properties must be
characterized and controlled in order to ensure optimized textural/sen-
sory experiences for the consumer and ensure issue-free processing [5,
6]. Due to the multiple length scales and time scales of interest in pro-
tein aggregate formation, the need arises for different techniques that
span these wide ranging length and time scales. This article will review), PathakJ@medimmune.com
. This is an open access article underthe progress made in the understanding of protein particle formation
and advances made in analytical techniques and analysis methods
that allow the development of new insights into the formation of pro-
tein particles and their corresponding properties-size, structure, micro-
structure, and rheology.
2. Native and non-native aggregation: reversible and (effectively)
irreversible aggregates
Proteins can self-assemble in a number of ways. They can formhigh-
ly speciﬁc, structured complexes such as receptors with ligands [7],
multimeric native states with or without metal complexation [8,9],
and multi-protein “machines” such as the ribosome [10]. Those types
of protein complexes typically have sufﬁciently strong inter-protein in-
teractions that one must work at extremely dilute conditions in order
for the complex to not be the natural or “native” state.We do not review
such systems explicitly here, as a majority of pharmaceutical proteins
currently or recently in development do not associate so strongly unless
it is via non-native conformers [11–13].
When self-association of native or folded proteins occurs in pharma-
ceutical products or model proteins that mimic pharmaceuticals, it pri-
marily occurs via transient and relatively weak interactions that require
one to work at high concentrations (on the order of 10−3 M or larger)
[14–18]. In this case, one might consider an array of possible aggregate
species (dimers, trimers, tetramers, etc.) that interchange with one an-
other dynamically. These species are typically easily reversed simply by
moving to lower protein concentrations and/or slightly shifting the so-
lution pH or ionic strength to alter the charge–charge interactions be-
tween monomers [14,15,17,19]. As a result, one should anticipate thatthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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terized with ex situ methods that require dilution and/or a change in
solvent conditions (cf. discussion below) will likely not be quantitative-
ly, or possibly qualitatively, representative of the aggregate popu-
lation(s) that exists in situ.
For purely reversible aggregates, one often can ignore the precise
mechanism – i.e., the detailed steps and the order in which they occur
in at a molecular level – if the time scales for equilibration of the aggre-
gate population are short compared to that for production and storage
of protein products such as pharmaceuticals. That is, one may only
need the equilibrium aggregate size distribution, or equivalently the
concentration of each species (monomer, dimer, trimer, tetramer, etc.)
if the system equilibrates quickly [20]. For a simple diffusion-limited
biomolecular reaction M +Mj↔Mj + 1 (M= monomer, Mj = oligo-
mer composed of j monomers), the characteristic time scale for equili-
bration of such a “reaction” may be expected to be too small (≪1 s)
to resolve with many experimental techniques that are in current prac-
tice (cf. discussion below). However, this is an important consideration
when selecting techniques to monitor/detect/quantify aggregation, and
when interpreting the results. Depending on the choice of experimental
technique and analysis methods, one can reach quite different conclu-
sions regarding the size and concentration of different oligomers or
“clusters” [14,16,21]. In general, one requires systematic and detailed
experimental characterization over a wide range of protein concentra-
tions in order to reﬁne even simple mass-action or multimer-
equilibrium models with any quantitative certainty [17,20].
Not all aggregates are reversible. In some cases, what might be
thought of as otherwise reversible aggregates can convert to stable
species that are “bound” together so strongly that they are effectively
irreversible on practical time scales and concentration ranges. In prac-
tice, this typically manifests as aggregates that do not dissociate appre-
ciably upon multi-fold dilution or upon shifts in solution pH or ionic
strength — although, the latter can cause aggregates to grow dramati-
cally [22,23]. Furthermore, creation of such aggregates typically in-
volves changes in the secondary and/or tertiary structures of the
constituent monomers in a given aggregate species. These structural
changes do not need to involvemore than a (small) portion of the over-
all monomer chain(s) [24–26]. In the case of small proteins, there is
often amarked increase beta-sheet content [27–30], but in general it re-
mains unclear precisely what structural changes are required to create
net-irreversible aggregates. High concentrations of chemical denatur-
ants (urea, guanidinium, ionic surfactants, etc.) or high pressures
(N103 bar) are sometimes able to dissociate such aggregates [31–33].
In such cases, small aggregates (dimers, etc.) may initially form as re-
versible species, but ultimately one often recovers or detects only the
net irreversible species in most experimental techniques that resolve
the different species from one another. In such cases, the
mechanism(s) of aggregation become important because changes in
the relative rates of different steps in the overall aggregation process
can dramatically shift the population (concentration) of different sized
aggregates, as well as potentially affecting the structure/morphology
of the aggregates that are detected [34]. The next section provides addi-
tional details regarding illustrative aggregation mechanisms as a
context for the discussion below regarding the importance of
mechanism(s) and what controls them when one is considering how
best to monitor and quantify protein aggregates.
3. Illustrative mechanisms of non-native aggregation
This section provides a brief overview of some the mechanisms by
which non-native aggregates form. It is not realistic to exhaustively
enumerate all conceivable aggregation mechanisms within the avail-
able space, nor is it necessary, as the examples below illustrate key
conceptual approaches that aid when interpreting experimental results
for aggregating systems. Inwhat follows, the term non-native aggregate
will be synonymous with net-irreversible aggregate, althoughreversible intermediates can also be involved (see below). Net-
irreversible protein aggregation is described without explicit formation
of new covalent bonds. While changes in covalent bonds can promote
aggregation [35–37], the rate limiting step(s) inmany cases involve for-
mation of non-covalently linked aggregates prior to covalent linkages
forming that further stabilize the initial aggregates [38]. That notwith-
standing, aggregation mechanisms are conceivable in which non-
covalent bond formation is rate-limiting, and therefore can be impor-
tant from both the perspectives of kinetics and the resulting aggregate
morphology [39,40].
Many of the recent studies with pharmaceutical proteins that form
larger aggregates do not require covalent bonds to form between pro-
teins, although some examples for mimics of food systems show a mix
of behaviors [39,40]. The discussion below does translate, in qualitative
terms, to aggregates that form by covalent linkages, although the de-
tailed kinetics and time scales involved can be quite different [34]. To
try to maintain as much generality is possible, most of the discussion
below is cast in terms of relative rates of different steps, as it is only
the relative rates that ultimately determine which competing
pathway(s) are ultimately observed for a given protein and a given so-
lution condition or storage environment.
Fig. 1 shows a schematic representation of a number of the key steps
involved in competing pathways of protein aggregation that have been
shown or speculated in the recent literature (see also, Figure caption),
and adapted from [41,42]. Alternative representations are also possible,
andmany of the publishedmechanisms that have been validated in de-
tail are similar to or essentially the same as in Fig. 1 [34]. Double arrows
for any steps in the diagram indicate net reversible steps. Single line ar-
rows represent net irreversible steps, with ellipsis indicating a series of
similar or analogous steps. Block arrows indicate steps that may be
poorly or only qualitatively deﬁned to date, and may involve multiple
steps that are lumped into one block arrow.
Starting with folded monomer protein (blue), the monomers could
conceivably form weak, easily reversible folded dimers or small oligo-
mers (Fig. 1). Alternatively, a foldedmonomer is able unfold or partially
unfold (red) and refold dynamically while in solution. The partly un-
folded monomers expose more hydrophobic amino acid sequences
that can help to drive initially reversible dimer or oligomerization
(Fig. 1), and ultimately if the different protein chains can ﬁnd ways to
form both strong hydrophobic contacts and satisfy their hydrogen
bonding needs (e.g., with inter-protein beta sheets) then they can
“lock” into net irreversible, non-native oligomers that can stay as just di-
mers/oligomers or can grow through different mechanisms. If one con-
siders sufﬁciently high concentrations then it may be feasible that
otherwiseweakly bound native oligomerswill become sufﬁciently pop-
ulated to be the faster pathway for transitioning from reversible oligo-
mers to irreversible ones (Fig. 1) [43], although that would require a
rather complex process of a native oligomer sufﬁciently unfolding and
then misfolding as a cluster to form the non-native oligomer(s) that re-
main stable or grow to much larger sizes.
In qualitative terms, growth can ﬁrst be categorized as dominated by
monomer addition or by aggregate–aggregate coalescence (cf. labels in
Fig. 1). In the former case, electrostatic repulsions between aggregates
are sufﬁciently large that aggregates do not aggregate with one another
except if one exhausts the available monomer pool [30,41,44,45]. In the
latter case, aggregates are sufﬁciently attracted to one another that
monomers are only consumed by the creation of newdimers/small olig-
omers, and those small aggregates rapidly coalesce with one another to
form larger aggregates that propagate the aggregate coalescence pro-
cess [44–48]. In the extreme, interactions between aggregates can be-
come so favorable that the aggregates undergo bulk phase separation
to form macroscopic and microscopic/subvisible particles [22,23]. Of
course, thesemechanisms can also occur simultaneously and so the be-
havior can change over the course of time as a sample is stored [44,45].
If one also considers aggregate formation via bulk interfaces, then
the following qualitative features summarize key ﬁndings from a
Fig. 1. (Top) Schematic overviewof competing aggregationmechanisms that have been shown explicitly or hypothesized for proteins such asmonoclonal antibodies at both low and high
protein concentrations. It is important to note that the same protein can follow different mechanisms just by shifting solution pH or salt concentration [25,41,45], and may or may not
follow the same pathway when exposed to different “stress” conditions such as: elevated temperature [34,57,101], adsorption to bulk solid/vapor/liquid interfaces [49–51,57,58], and
even cold temperatures where cold-unfolding can promote aggregation [102]. One also anticipates that dramatically increasing the protein concentration could drive formation of native
oligomers [43,103] that may be on-pathway precursors to non-native aggregates. (Bottom) Simple scheme illustrating formation of a protein layer at a bulk ﬂuid or solid interface with a
parent aqueous protein solution,with large particles forming as interdigitated protein “patches” shed from the interface over time— e.g., as a result of agitation of the surroundingﬂuid, or
compression/dilation of the ﬂuid–water interface. It is important to note that multiple pathways may be “active” simultaneously for a given protein and sample condition.
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between water and solids (e.g., glass, plastic, metal, ice), liquids
(e.g., silicone oil), and vapor (e.g., air or N2 headspace) [49–55]; (2) for-
mation of large aggregates/particles can be accelerated by turnover of
proteins at the interface via convective mass transfer [56,57], by
compressing/dilating the interface [51], and/or by creation/destruction
of the interface (e.g., by bubbles forming/bursting) [57,58]; (3) to a
ﬁrst approximation, the rate at which the concentration of large aggre-
gates increases over time in such “stressed” samples is proportional to
the amount bulk interfacial area between the protein solution and
whatever solid/vapor/liquid it is in contact with; (4) one does not typi-
cally observe large increases in much smaller aggregates (e.g., dimers,
oligomers) during these types of experiments. The mechanistic details
of how protein gets to/from the interface(s), whether it is folded or un-
folded en route to the interface and at the interface, the structure of the
protein layer(s) at the interface, and how large particles that are detect-
ed in the bulk liquid are formed from the protein molecules at theinterface are all questions that have not been generally answered to
date. As such, Fig. 1 (bottom) does not attempt to capture those in
mechanistic detail, and only indicates that protein interactions with
bulk interfaces have been implicated in many studies to date (an illus-
trative selection are cited above).
What follows from Fig. 1 is that different mechanisms compete with
one another, and it is not clear a priori which mechanism or mecha-
nisms will be most relevant for a given protein in a given solution or
sample environment. The next subsection addresses a question that ap-
pears to have been overlooked, or at least not highlighted in the litera-
ture, to the best of our knowledge. Speciﬁcally, a given mechanism
dictates how aggregation proceeds from monomer to small aggregates
to larger ones, and so on. The resulting material balances or population
balancesmust be adhered to, and therefore one cannot simply obtain an
arbitrary distribution of aggregate sizes (characteristic dimension R [=]
nm) and aggregate masses (average molecular weight Mw or average
mass-per-particleMp). This restricts the practical “operating space” for
Fig. 2. Illustrative diagram for how simplematerial balances highlight that differentmech-
anisms result in aggregate size and population (concentration) distributions that can be
dramatically different. The curves represent solutions to the material balances for when
differentmechanisms dominate: small oligomer (dimer, trimer, etc.) formation and possi-
ble growth by monomer addition (blue); rapid coalescence of oligomers (dimer, etc.) as
soon as they form (red); particle shedding from protein (mono)layers at bulk interfaces
(black and green). The calculations shownhere for the bulkmechanisms use an initial pro-
tein concentration of 1.5 g/L, assuming a 150 kDa protein such as a MAb. If one used
150 g/L for the starting concentration, all blue and red curves are shifted up by 2 orders
of magnitude on the y axis; green and black curves do not depend on initial protein con-
centration for the simple example here.
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with existing experimental techniques.
4. Aggregate concentrations and sizes are not independent—mech-
anisms matter
As noted above, the underlying aggregationmechanism restricts the
possible combinations of aggregate population sizes and concentra-
tions. As an illustration we consider aggregation pathways that can be
described either as bulk-mediated aggregation, which occurs in solu-
tion, or as surface-mediated aggregation, which occurs at an interface
(e.g. glass–liquid interface). If a solution is not seeded with aggregates,
a mass balance or population balance of the aggregate growth process
in bulk solution results in the concentration and average mass-per-
aggregate for all possible sizes of aggregates in solutions [48,59]. For
surface-mediated aggregation, a simple mass balance on the control
volume (the glass syringe or vial) can be used to relate the average ag-
gregate mass and concentration (i.e., particle counts per mL) in a semi-
quantitative manner. In both the surface-mediated and bulk-mediated
pathways, a mass balance results in fundamental coupling of aggregate
mass and concentration. In the interest of brevity and space limitations,
themathematical description of these balance equations and their solu-
tions is provided in Supplementarymaterial, aswell as the original pub-
lished reports for the bulk-mediated case [41,44,48,59].
In bulk-mediated aggregation, the full mass balance model for ag-
gregation was previously distilled into moment equations in which
the entire aggregation mechanism is explained in terms of competing
processes: nucleation, growth by monomer addition or chain polymer-
ization (CP), and growth by condensation or aggregate-association po-
lymerization (AP) [48]. The moment equations relate the monomer
concentration, the overall concentration of aggregates, and aggregate
weight-average molecular weight to the aggregation rate coefﬁcients
or characteristic time scales for nucleation, and those for growth by CP
and AP. A nucleation event creates a new aggregate while consuming
monomeric protein. Growth by CP consumes monomers and increases
the aggregate mass, but leaves the overall aggregate concentration un-
changed. A condensation or AP event takes two existing aggregates to
create a single larger aggregate (e.g., a dimer and a decamer create a
dodecamer). Each condensation event necessarily decreases the net ag-
gregate concentration. During aggregation for pharmaceutical proteins,
all three mechanisms can occur simultaneously, but at different rates
[45]. By varying the ratio of the rate coefﬁcients or time scales for each
process, one can determine realistic ranges of aggregate concentration
and molecular weight that bound the expected behavior for real sys-
tems. Finally, by choosing a realistic fractal dimension (ν) for the aggre-
gates [30,44,46], one can bound the “space” of realistic ranges for
average aggregate or particle size (e.g., radius of gyration, Rg) and con-
centration. Previous scattering results for a number of protein systems
have reported aggregate morphologies that range from insulin amyloid
ﬁbrils [60] (ν ~0.65) to aCgn or IgG amyloid aggregates that resemble
short or long ﬂexible chain-like polymers [30,44] (ν ~0.75) and IgG ag-
gregate clusters [46,61] (ν ~0.4).
A surface-mediated aggregation pathway can be driven, for exam-
ple, by the favorable interaction of the hydrophobic interface (e.g., air–
water) and the hydrophobic patches in the protein, whichmay become
exposed during adsorption. Aggregates or particles are speculated to
form either on the bulk interface, or as unfolded/misfolded proteins de-
sorb from the interface, although the precise mechanism remains de-
batable. The impact of air–liquid and solid–liquid interfaces on
rheology is described in detail in Section 7. In this section, the discussion
is limited to aggregation kinetics as it relates to bulk interfaces.
Fig. 1 (bottom panel) illustrates a simple thought experiment:
(i) proteins adsorb at the interface and some or all unfold and interdig-
itate to some degree, forming a “ﬁlm” over time; (ii) the ﬁlm may or
may not be ﬂexible, but upon sufﬁcient “stress” such as due to deforma-
tion of the surface or rigorous agitation to aid desorption, portions of theﬁlmwill “shed” or break off from the surface; (iii) these “patches” of the
ﬁlm that have been shed from the bulk interface will not stay extended
as sheets once back in solution, but instead will “crumple” into higher
fractal dimension objects, or may “bundle” in extended ﬁbril-like ob-
jects; (iv) available detection techniques (see below) typically monitor
only the particles that ﬁnd their way back into the bulk solution. As a
worst-case scenario – i.e., highest particle counts for a given particle
size – a simple mass balance states that if the entire ﬁlm breaks into
equally sized “patches”, then the number of particles (N) is equal to
the area of the initial ﬁlm divided by the average area of a patch. The
concentration of particles or aggregates is N divided by the liquid vol-
ume (~1mL or ~10mL for a pre-ﬁlled syringe or a small vial, respective-
ly). The averagemass per particle (Mp) is equal to the patch area divided
by the area-per-protein (roughly πσ2/4, with σ= effective protein di-
ameter), andmultiplied by the proteinmolecularweight. The character-
istic size of the particles then follows from the choice of fractal
dimension for the “crumpled” or “bundled” patches that shed from
the protein ﬁlm(s).
Fig. 2 shows the range of average Rg and total (molar) concentration
of aggregates for bulk- and surface-mediated aggregation mechanisms,
calculated based on the discussion above, and assuming only a small
amount of monomer loss (e.g., 1% for bulk-mediated aggregation) so
as to be in keeping with pharmaceutically acceptable levels. For
surface-mediated aggregation, the amount of monomer loss is much
less than 1%, as the calculations are based on a monolayer of protein
adsorbing and the breaking off as “patches” from a ﬁlm.
Bulk-mediated aggregation has a family of curves, with each curve
representing a different set of ratios of the rate coefﬁcients for nucle-
ation, CP and AP. The red family of curves follows from nucleation
+ CP, while the blue set of curves follows from nucleation + AP. The
curves calculated for surface-mediated aggregation are based on the es-
timated solid–water interfacial area for the residual bubble in a 1mL cy-
lindrical preﬁlled syringe with 0.23 cm i.d. (black curve) and for the
stagnant air–water interface a 10 mL cylindrical vial with an i.d. of
1.1 cm (green curve). These provide upper estimates for the concentra-
tion of aggregates (y-axis in Fig. 2) compared to, e.g., the amount of air–
water interface in a pre-ﬁlled syringe or stagnant vial. Changing the
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axes in the Figure, but the general size and concentration ranges remain
essentially unchanged. The results in Fig. 2 use a representative value of
(ν= 0.66), and illustrate that it is natural to expect “gaps” in the acces-
sible size-concentration space for aggregates/particles, based on differ-
ent aggregation mechanisms. The sections below include discussion of
how this concept ties into the practical and fundamental aspects of de-
tecting, quantifying, and characterizing protein aggregates/particles, as
well as means to control their formation.
It is worth noting that in the case of surface mediated aggregate or
particle formation, one could easily conceive of additional features in
the model or mechanism — e.g., renewal of the protein ﬁlm after shed-
ding; only a fraction of protein molecules at the surface creating aggre-
gates; the ﬁlm not shedding as equally sized particles; etc. Only a simple
model was applied above, as currently there is no experimentally vali-
dated mechanism available that addresses these issues. Therefore, the
results in Fig. 2 should be considered illustrative, and are provided as
simple graphical representation of the fact that the size and the concen-
tration of aggregates are not completely independent once one con-
siders the question of “how” the aggregates formed.
5. Characterization techniques: protein aggregation: thermodynam-
ics, kinetics & aggregation mechanisms
One of the key requirements in formulation screening in the
biotherapeutic area has been to understand the aggregation propensity
and phase behavior of protein formulations, through exploring various
thermodynamic properties that are accessible experimentally on practi-
cal time scales. There has been a signiﬁcant amount of recent work in
this area by a number of different groups focusing on developing and
applying different data analysis methods to light scattering data in
order to obtain thermodynamic parameters that are indicative of the
strength of protein–protein interactions. Thermodynamic parameters
of interest that have been obtained through such analysis and applied
to quantifying protein–protein interactions include a set of related
quantities: the osmotic second virial coefﬁcient (B22) and reduced os-
motic second viral coefﬁcient (B22/BHS); Kirkwood Buff integrals
(G22); and the so-called interaction parameter (Kd) [62,63]. Although
the analysismethod varies in order to obtain these different parameters,
they are all primarily obtained through light scattering techniques.
There are two modalities of light scattering — dynamic light scattering
(DLS) and static light scattering or (SLS). In DLS, the intensity ﬂuctua-
tions of light scattered from particles moving due to Brownian motion
is measured, while in SLS the time averaged intensity of scattered
light at a certain angle is measured. Measurement of either the protein
osmotic second virial coefﬁcient or Kirkwood–Buff integral can be ob-
tained through static light scatteringmeasurements by varying the pro-
tein concentration, while Kd can be obtained through DLS to measure
the collective diffusion coefﬁcient as a function of protein concentration.
The thermodynamic parameters obtained from these light scattering
techniques can provide indicative trends in terms of relative stability
of different protein formulations. In the case of virial coefﬁcients, equi-
librium analytical centrifugation can also be employed.
Understanding and controlling aggregation kinetics is another key
aspect to gaining insights into the aggregation mechanism and the
resulting ﬁnal aggregate microstructure[6,41]. Protein denaturation
and aggregation brought about by isothermal incubation is often times
the desired method in order to probe the aggregation kinetics. DLS
and size exclusion chromatography (SEC) with multi-angle laser light
scattering (MALLS) are increasingly being utilized in order to perform
suchmeasurements, as well as complementary techniques such as ana-
lytical centrifugation [64]. SEC is a robust analytical technique in which
proteins are separated, in principle, by their hydrodynamic volume. It is
a commonly used technique that is utilized in the pharmaceutical in-
dustry to quantifymonomer loss. MALLS is a static light scattering tech-
nique inwhich scattered light ismeasured atmultiple angles. The angle-dependent scattered light information provides the radius of gyration
(Rg) and weight average molecular weight of the scattering species.
MALLS is especially relevant for high molecular weight species where
the scattering depends on the scattering angle.
The combination of these two techniques provides a powerful tool to
separate and characterize the highmolecularweight aggregates formed
during the protein aggregation process and help provide insights into
the aggregationmechanism. In addition to simply usingMALLS to assign
a molecular weight to separable peaks in SEC, this approach can also be
used to characterize HMW particles or aggregates that co-elute in SEC
[65]. Li et al. illustrated that the combination of SEC-MALLS and extrac-
tion of weight average molecular weight, radius of gyration, apparent
polydispersity and mass fraction of monomer provide necessary signa-
tures to distinguish between different aggregation mechanisms (chain
polymerization vs cluster–cluster aggregation) responsible for the for-
mation of the HMW aggregates. Measurement of the aggregate charac-
teristics utilizing SEC-MALLS was all carried out on quenched samples,
where the sample was heated to a speciﬁc temperature and quenched
in ice-water at different time points to capture the aggregate character-
istics at that time point. Although this allows determination of aggre-
gate size at a speciﬁc time point in the aggregation process, it is also
desirable to measure the size evolution as the sample is held in situ at
the incubation temperature, or as the sample is heated up to the incuba-
tion temperature. This can be achieved in the measurement through
DLSmeasurements in a closed cell Peltier. A similar approach of utilizing
both SEC-MALLS and DLS to characterize size of HMW aggregates was
lucrative for food protein systems — e.g., whey protein, in addition β-
lactoglobulin [66].
Although a detailed discussion is beyond the scope of this review, it
should be mentioned that understanding the secondary and tertiary
structural changes associated with aggregation is essential in order to
further obtainmechanistic insights into the aggregation process and es-
tablish the underlying ‘cause’ for aggregation. These are often times uti-
lized in addition to DLS and SEC-MALLS, serving as complimentary
techniques to both follow size/microstructural changes and second-
ary/tertiary structural changes [62] Common techniques for elucidating
structural changes in aggregating proteins include, Fourier Transform
Infrared Spectroscopy (FTIR), Circular Dichorism (CD), Intrinsic Fluores-
cence (FL), and Raman Spectroscopy. FTIR provides information primar-
ily on secondary structure, while CD and Raman can provide
information on both secondary and tertiary structures, provided one
can obtain sufﬁciently high-quality data. FL spectra provide information
regarding primarily local tertiary structure in the vicinity of tryptophan
and tyrosine side chains. CD measurements to obtain secondary struc-
tural information require data in far-UV region, while those for tertiary
structure information require data in near-UV region. Raman and FTIR
spectroscopy are both based on the vibrational spectra of proteins in so-
lution.With current commercially available equipment, CD and FLmea-
surements require orders of magnitude lower protein concentrations
than those for Raman or infrared spectroscopy. Raman spectroscopy
has advantages over FTIR for protein systems, as the relative back-
ground signal contribution of water is stronger in FTIR then in Raman.
Raman spectroscopy can be carried out for solutions, gels and solids
and this has clear advantages in studying aggregation for proteins sys-
tems that enter into a gel phase as aggregation progresses.
The DLS approach discussed above yields size and polydispersity in-
formation at the earlier stages of aggregation. However, the data analy-
sis at later stages becomes highly challenging due to the presence of
multiple scattering as the samples become turbid as high concentra-
tions of HMW aggregates can occur. This issue has been addressed to
a certain extent through two relatively new developments in DLS-
backscattering and 3D cross correlation. In the backscattering approach,
the scattered light is detected at a higher angle (e.g. 173°) and the
scattered light is measured close to the cuvette wall, thereby allowing
more turbid samples to be probed. This approach allows DLS measure-
ments to be carried out on moderately turbid systems during early
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ermicrorheologymeasurements[67]. In 3DCross Correlation,[68] single
scattering data is obtained from turbid samples through simultaneously
carrying out two light scattering experiments at the same q vector (scat-
tering vector) and same sample volume and cross correlating the mea-
sured scattered intensities from both experiments with each other. This
ensures that only single scattering contributes. This measurement has
been extended to multiple angles [68] that allowed time resolved stud-
ies on aggregating systems to be carried out. The authors illustrated the
utility of the technique in providing insights into the temporal evolution
of aggregation in acidiﬁed skim milk for yogurt production. This tech-
niquehas not yet been extended to investigating the temporal evolution
of aggregating therapeutic protein formulations, but is clearly an area
where new insights into the aggregation kinetics could be envisioned
as many of the formulations exhibit signiﬁcant increase in turbidity as
aggregation progresses under stressed conditions.
More detailed understanding of the interaction potentials, micro-
structure and morphology of the formed protein particles however re-
quires techniques that expand the q-vector (q = (4πn / λ)sin (θ / 2),
where n is the refractive index, λ is thewavelength, and θ is the scatter-
ing angle) range of the scattering techniques, as the length scales of the
formed structures, the time scales of relaxation mechanisms, and the
distances over which interactions occur can vary signiﬁcantly through
the aggregation process; this can eventually lead to arrested dynamics,
network formation, etc. Experimentally following these processes
therefore requires the utilization of techniques such as small angle neu-
tron scattering (SANS), small angle X-ray scattering (SAXS), Ultra Small
Angle Light Scattering (USALS), and electron microscopy. The length
scales usually probed by SAXS is in the range of 10–1000 Å for and
that usually probed by SANS is 10–200Å. Light scattering usually probes
lengthscales in the 2000 Å to 100 μm range. These techniques are in-
creasingly being utilized in both the food and biotherapeutics area to
provide additional insights into the phase behavior and microstructure
evolution of aggregating protein systems.
Small Angle Neutron Scattering (SANS) allows an understanding of
the interactions in protein systems through an analysis of the structure
factor. The structure factor S(q) obtained from a SANS experiment is de-
termined by the ensemble-averaged interparticle distance and interpar-
ticle interactions. An analysis of the structure factor therefore allows a
more detailed understanding of the extent of the speciﬁc type and
range of interaction present in the speciﬁc protein system and under
speciﬁc formulation condition. The location of the structure factor
peak and its subsequent ﬁtting to a relevant interaction potential can
in turn lead to generation of a hypothesis regarding the microstructure
state of protein aggregate. One of themost prevalent recent hypotheses
in the protein self-assembly ﬁeld has been the interpretation of struc-
ture factor peaks based on the formation of equilibrium clusters in con-
centrated protein solutions. This experimental observation and data
interpretation were ﬁrst done by Stradner et al. [21], where the peak
at high q was attributed to lysozyme monomer interactions within a
single cluster and the peak at low qwas attributed to cluster–cluster in-
teractions. However as discussed in the review by Mezzenga [5], al-
though there have been multiple subsequent studies utilizing other
techniques such as light and X-ray scattering that support the cluster
hypothesis, there also have been alternate non-cluster based interpreta-
tions of SANS data as well. One of the earlier studies is based on SANS
work done by Shukla [69], where they observed a concentration-
dependent shift in the SANS scattering peak and postulated that the
peak can be attributed to lysozyme monomer interaction interacting
via short range attraction and long range screened electrostatic
repulsion.
The utility of SANS as a tool to understand the interaction potentials
and microstructure in high-concentration protein systems has recently
been extended to therapeutic proteins such as monoclonal antibodies,
primarily with a view to understanding viscosity increases in these sys-
tems as a function of protein concentration and formulation conditions.Yearly et al. [19] carried out SANS measurements on two monoclonal
antibodies (named as MAb1 and MAb2 respectively) which differed
by small sequence alterations but exhibited very different patterns of
howviscosity increasedwith increasing concentration (MAb1 exhibited
signiﬁcantly higher viscosity increases with concentration than did
MAb2). A detailed structure factor analysis allowed the authors to gain
insights into the different protein–protein interactions (PPI) present in
these two different proteins and how that was impacted by concentra-
tion. It was shown that the MAb1 PPI changed from strongly attractive
net potential at small volume fractions to a PPIwith negligible attraction
at high concentration. This then led to the postulation of the formation
of dynamic clusters which in turn gave rise to higher viscosity than
MAb2, as the PPI for MAb2 were dominated by charge repulsion be-
tween monomers. In addition to a detailed structure factor analysis,
the authors developed an analytical three-arm form factor for monoclo-
nal antibodies which addresses the problem of deconvoluting the form
factor and structure factor in a numerically practical manner. To further
support SANS analysis of protein data, Clark et al. [70] also carried out
molecular Monte-Carlo simulations together with molecular dynamics
simulations to gain further insights into intermolecular and intramolec-
ular interactions that impact functional performance of these therapeu-
tic proteins. SANS is a potentially powerful tool that, together with
theoretical developments and atomistic molecular simulations and
free energy analysis, is expected to provide new insights into the inter-
actions and microstructural evolution in concentrated protein
formulations.
Similarly, small angle X-ray scattering (SAXS) is a potentially pow-
erful technique for advancing the understanding the therapeutic pro-
tein formulation stability. Although the technique has previously
provided information mostly on static solution structures or bead
model representations of proteins, a recent study [71] has extended
the technique to infer the effects of solution conditions (ion type, pH)
on antibody protein dynamics in solution and on stability. As SAXS rep-
resents the average scattering pattern from all molecular conforma-
tions (as does SANS), data interpretation can be complicated. The
authors employed an ensemble-optimized method (EOM) to deter-
mine the conformational space of an IgG protein under changing for-
mulation conditions. The EOM allows optimization of the ﬁt of the
scattering data by comparing and optimizing the averaged individual
scattering patterns from different conformers with real SAXS data
from the protein solution. This analysis allowed the molecular ﬂexibil-
ity around hinge region of monoclonal antibodies to be determined
under the inﬂuence of different kosmotropes and chaotropes in solu-
tion and led to an understanding of conformational dynamics and sta-
bility for the speciﬁc IgG protein.
The self-assembly and aggregation processes seen in both therapeu-
tic and food protein systems due to thermal or chemical treatments
eventually can lead to a liquid–solid transition and to the formation of
a gel. The microstructural and morphological changes associated with
these processes require utilization of techniqueswhich allow the visual-
ization/probing of the large length-scale structures associated with
these processes. The key techniques which have been utilized exten-
sively in the food protein area have been based on microscopy. The
key microscopy techniques of interest have been scanning electron mi-
croscopy (SEM), transmission electron microscopy (TEM), and confocal
microscopy. The techniques have illustrated that for globular protein
gels formed from food protein systems, themorphology tends to be pri-
marily particulate or ﬁne stranded. The morphology that will form is
strongly dependent on the ionic strength/charge conditions of the for-
mulation. At conditions close to the iso-electric point or at high ionic
strength, the microstructure consists of associated spheres forming rel-
atively compact clusters. At conditions of high electrostatic repulsion
the gels that are formed are more ﬁlamentous or worm-like networks.
[6]. Although the mentioned microscopy techniques have limitations
e.g. viscosity issues in utilizing cryo-TEM, they provide a relatively direct
route for probing the morphological changes associated with
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mechanism(s) and observed rheological properties.
Moving from molecular-scale aggregation to bulk phase separation,
an improved understanding of the liquid–solid transition process has
also been progressed based on utilization of novel light scattering tech-
niques such as Ultra Small Angle Light Scattering (USALS) [72]. USALS
allows static light scattering to be carried out over a scattering vector
range corresponding to 0.1 μm−1 b q b2 μm−1. The scattered intensity
behavior over this q range allows the following of a spinodal decompo-
sition process and capturing of the changes in a characteristic micro-
structural lengthscale, ξ, associated with this process. Gibaud has
utilized this technique together with video microscopy to follow liq-
uid–solid transition in lysozyme solutions. The combination of these
two techniques allowed them to demonstrate the formation of an
arrested bicontinuous network when the solution was quenched. They
were also able to show that the correlation length exhibited a tempera-
ture dependence that closely followed the critical scaling expected for
density ﬂuctuations during early stages of spinodal decompositions.
This approach can be a useful tool for interrogating liquid–solid transi-
tions that are seen in therapeutic protein formulations, but to the best
of our knowledge has yet to be employed in that context.
6. Characterization techniques: protein particle detection and size
Protein particles formed as a result of aggregation can spanmany or-
ders of magnitude from oligomers spanning tens of nanometers all the
way to visible aggregates spanning several hundred micrometers [3,4].
It is clear that one single analytical instrument cannot be utilized to cap-
ture this wide range of length scales. Even more challenging is the fact
that within a certain size range, the actual distribution of particle sizes
and concentrations of particles of a particular size are difﬁcult to obtain
due to limitations of some of the techniques being utilized [4].
In themonomer-to-oligomer size rangewhich can span from several
nanometers to tens of nanometers, sizing and a quantiﬁcation of the
polydispersity in the particle sizes have traditionally been carried out
by light scattering techniques either independently or in combination
with a separation technique such as SEC and Field Flow Fractionation
(FFF)[65,73]. The following sections highlight the relevant techniques
for the various size ranges of particles or aggregates that are
encountered.
6.1. Protein particle sizing: 1 nm–2 μm
a) Dynamic Light Scattering (DLS)
Light scattering has been discussed in the context of following the
protein aggregation mechanism. Once aggregates are formed or in sys-
temswhich do not undergo aggregation DLS can provide useful size and
polydispersity information formonomers/oligomers and particles span-
ning between 1 nm and 1 μm. As already discussed cuvette based DLS
measurements can allow the following in-situ of size changes when a
protein undergoes aggregation. There are however limitations in DLS
in the sense that size distribution obtained from DLS is biased towards
larger particles due to dependence of the intensity to the sixth power
of the diameter. This can however be advantageous if the objective is
the detection of small quantities of large particles. In SLS one obtains a
z-average molar mass, which can make it difﬁcult to understand quan-
titatively the relative contribution of different species present in the for-
mulation. Combination of these techniques with a separation technique
such as SEC enhances the resolution and allows better separation of the
contribution of different size particle populations.
b) Nanoparticle Tracking Analysis (NTA)
Some of the issues highlighted with dynamic light scattering based
particle sizing, such as bias to larger particles can be overcome through
complimenting the measurements with novel developments in particletracking [4,74]. Nanoparticle Tracking Analysis or NTA utilizes laser illu-
mination to track the Brownianmotion of deeply submicron nanoparti-
cles in liquids. The laser illumination can be through using of a 405, 532
or 638 nm light source and the particlemovement is detected through a
CCD camera. A modiﬁed Stokes–Einstein equation is employed in order
to obtain the particle size from the mean squared displacement of the
particle. This particle-by-particle approach provides both a high resolu-
tion particle distribution and measures concentration. The size range
covered by NTA is between 30 nm and 1 μm. The lower size limitation
is inﬂuenced by the refractive index of the particles. For low refractive
index particles, such as protein particles, the lower limit is usually in
the 40–50 nm size range. The clear advantage that NTA presents is in
the ability to picking up the differences in particle tracks in different
parts of the sample. This is especially important in heterogeneous sam-
ples such as protein formulations.
The applicability of the NTA in carrying out size characterization of
protein particulates is not only limited to spherical shape aggregates,
but has been extended to look at ﬁbrillar aggregates in a recent study
carried out by Yang et al. [75]. In that study, NTA based particle sizing
was carried out for DNA and Transthyretin a 56 kDa homotetrameric
protein. For the DNA sample, which has a large aspect ratio and can be
modeled as a semiﬂexible (wormlike) chain, the peak in the size distri-
butions from NTA was at 178 nm and 32 nm. The authors considered
this as excellent agreement with the size calculated from the semiﬂex-
ible chain model. The concentration of ﬁbrils obtained from NTA was
however quite signiﬁcantly underestimated. According to the authors,
the extended dimensions of DNA lead to interference effects. This
leads to a decrease of the scattered intensity of many DNA particles
below the threshold of detection, leading to signiﬁcant undercounting.
As however illustrated by the authors, combining NTA with DLS data
does allow the extraction of meaningful concentration information.
Overall the technique together with DLS shows good promise as a tech-
nique to measure protein particulate size distributions allowing further
insights into protein aggregation kinetics and mechanisms.
c) Resonant mass measurement (RMM)
ResonantMassMeasurement (RMM) is a techniquewhich adds fur-
ther quantiﬁcation of protein particles in the size range between 50 nm
and 2 μm. The technique is based on a microchannel resonator[76].
When a particle moves through the microchannel it causes a change
in the resonance frequency of the microcantilever. The net frequency
shift is proportional to the buoyant mass of the particle from which
the size can be extracted. The frequency shift in the resonance frequen-
cy is measured by a laser which is focused on the tip of the
microcantilever and the signal passed onto a photodiode detector. The
technique provides accurate measurement on a particle by particle
basis in the size range between 50 nm and 2 μm extending accurate
sizing to a range just below that of ﬂow microscopy. This starts to
then provide a good overlap and transition into sizing techniques in
the subvisible range.
6.2. Protein particle sizing: subvisible range N2 μm
The characterization of protein particles in the size range between 2
and 10 μm is increasingly growing in importance due to potential im-
munogenicity of particles in that size range. These include both protein-
aceous and non-proteinaceous particles. Techniques which are being
utilized to characterize particles in this size range include light obscura-
tion, coulter counter and ﬂow imaging or ﬂow microscopy.
Light obscuration is based on extracting the area/size of a particle
from the loss in intensity as a particle passes through the path of a
light beam. In a coulter counter the particle sizing is obtained from volt-
age impulse due to the resistance it induces as it passes through an or-
iﬁce with two electrodes. In ﬂow microscopy the particle count and
particle size distribution are obtained as a sample ﬂows in front of the
Fig. 3. Solution viscosity as a function of cluster size in systems of two different monoclo-
nal antibodies that exhibit reversible self-association. The linear dependence of viscosity
on cluster size, measured by light scattering, is beautifully demonstrated in these data
by the authors, Lilyestrom et al., J. Phys. Chem. B (2013) (Ref. [82]).
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sively in the subvisible size range and do provide useful size informa-
tion. However there are certain limitations regarding all of these
techniques [77]. The optical techniques-light obscuration and ﬂow im-
aging have limitations when characterizing protein particles at high
concentrations. These techniques tend to underestimate the particle
numbers due to the low refractive index of the protein particles in a
high concentration protein solution background. Additionally these
techniques in many cases do require dilution and that can result in arti-
facts especially for reversible aggregates that only form at high concen-
trations. Flow imaging orﬂowmicroscopy additionally has some further
limitations. As this is a ﬂowbasedmeasurement there are limitations on
the lower size that can be imaged/sized accurately. This limits sizing to
2–3 μmat the lower size end. Additionally resolution and picture quality
are not high due to limited depth of ﬁeld. Coulter counter can provide
size information reliably up to about 150 mg/mL however it does re-
quire the use of an electrolyte with sufﬁcient conductivity and some-
times underestimation of size is obtained especially for particles in the
smaller size end of the size range probed. Overall, the limitations of
these techniques under relevant buffer and high concentration condi-
tions still make sizing and characterization in this subvisible size range
highly challenging.
6.3. Characterize/distinguish proteinaceous and non-proteinaceous
particles
In addition to correct estimate of the protein particulate sizing as-
pect, it is important for protein therapeutic formulation safety and sta-
bility perspective to be able to distinguish between proteinaceous and
nonproteinaceous particles. One of the recent advances in this area
has been through the application of a resonant mass measurement
(RMM) technique based on a vibrating microcantilever which has al-
ready been discussed in an earlier section. The presence of a particle
on the resonating microcantilever causes a shift in the frequency. Posi-
tively buoyant particles such as silicone oil droplets can bedistinguished
from negatively buoyant particles such as protein particles as they
would cause either an increase or decrease in the cantilever frequency.
Recent study by Weinbuch [78] has illustrated the utility of the RMM
technique compared with the more standard micro-ﬂow imaging
(MFI) technique for detection and analysis of protein particulates and
silicone oil droplets. It should be mentioned that the size determination
and discrimination between proteinaceous and non-proteinaceous par-
ticles in MFI is based on very different principles then RMM. In MFI, 2D
particle images are captured and size determination is carried out based
on spatial dimension of the images deﬁned by the outer boundaries. The
discrimination between proteinaceous and non-proteinaceous particles
is based on particle shape and transparency. Based upon the compara-
tive studies carried out [78] it was concluded that RMM differentiation
was more appropriate for particles below 2 μm, while MFI differenti-
ation was more appropriate for particles above 2 μm. As the size
range of protein particles that can be encountered in therapeutic for-
mulations is very wide, complimentary use of both techniques was
recommended.
7. Rheology of therapeutic protein solutions
7.1. Scope
We focus exclusively on the bulk shear rheology of protein solutions
here while emphasizing the fact that amphiphiles like proteins adsorb
spontaneously at the air (A)/water and oil (O)/water (W) interfaces
(Fig. 1). Surfactants are commonly added to colloidally stabilize thera-
peutic proteins in solution by preferential adsorption, i.e. orogenic dis-
placement. Since surface adsorption can apparently inﬂuence the
measurement of the bulk shear rheology of surfactant-free protein solu-
tions, we shall brieﬂy address it later, given its importance to theformulation of bio-therapeutic proteins and peptides. We forgo discus-
sions of food protein solution rheology in this review and focus mainly
on therapeutic proteins.
We focus mainly on the shear viscosity, η, though other rheological
material functions in steady and oscillatory shear as well as creep defor-
mation also provide useful insights, but are more challenging for the
layman to comprehend. Moreover, while, the debate on whether pro-
tein molecules unfold in shear ﬂow still ensues and overlaps partially
with the intended scope of this review, space limitations preclude its
discussion.We refer interested readers to a recent review in this subject
area by Bekard et al. [79].
7.2. Soluble clusters and their effects on viscosity: reversible self-association
We ﬁrst scrutinize the effects of reversible self-association (RSA),
which often occurs in formulations of therapeutic proteins, and is com-
monlymitigated by addition of excipients or by varying pH and/or ionic
strength. RSA increases the viscosity of IgG solutions. Liu et al. veriﬁed
carefully the effects of RSA on solution viscosity thereby extending
the original results of Hall & Abraham [16,80], who focused on
hydrodynamics.
Themolecular underpinnings of increased viscosity, poorly elucidat-
ed hitherto in the literature, lie in the attractive inter-molecular interac-
tions that drive RSA. These attractive interactions effectively suppress
the mean squared displacement, br2(t)N, that molecules undergo dur-
ing time (t)-dependent Brownian diffusion; angular brackets denote
ensemble average. The reduced br2(t)N, is reﬂected in the diffusion coef-
ﬁcient, D≈ br2(t)N / τ, where τ denotes the relaxation time. Since the
Stokes–Einstein relationship predicts that D × τ should be constant,
we can therefore understand how reduced D leads to increased η. Con-
versely, when repulsive interactions prevail in a protein solution, they
facilitate diffusion and increase br2(t)N. Thus, D increases and η de-
creases in repulsive systems. Repulsive interactions are therefore desir-
able from both stability and low viscosity, especially from the bio-
pharmaceutical formulation perspective. Though the Stokes–Einstein
equation was derived for dilute systems, a generalized Stokes–Einstein
expression has been proposed for concentrated systems, wherein the
hydrodynamic size is replaced by a correlation lengthscale [81]. Themo-
lecular arguments proposed here therefore hold for both dilute and con-
centrated protein solutions.
As RSA creates soluble clusters, an obvious question lies in under-
standing the dependence of η on cluster size, N, the number of mono-
mers in a cluster. Lilyestrom et al. [82] have demonstrated that η ~ N
linearly in an IgG1 formulation with RSA (Fig. 3). For a formulation
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of a formulation comprising trimers (N= 3). Invoking a molecular in-
terpretation of viscosity enables easy rationalization of linear scaling
of η(N). Viscosity is an ensemble average measure of the friction coefﬁ-
cient (ζ) experienced by monomers and all soluble clusters during
Brownianmotion. The force per unit velocity experienced by the soluble
species, as ζ is deﬁned, scales with N. Thus, a soluble cluster comprising
N monomers experiences total friction of Nζ, and since viscosity itself
scales linearlywith ζ, the linear ζ(N) reported by Lilyestrom et al. is eas-
ily understood. This elegant prediction of Einstein's Brownian motion
theory describes the scaling of η(N). Nevertheless, the exact shape, lin-
ear vs branched, and conformation of the soluble clusters formed due
to RSA still need to be determined, since they are important determi-
nants of solution viscosity. Moreover, since the sedimentation behavior
of proteins and their clusters formed by RSA depend on both size and
shape, advances in the understanding of cluster shape, size and
charge/charge distribution will bridge the gap between experiment
and theory.7.3. Effects of sub-visible particles on viscosity
Until recently controversy seemed to prevail about the effects of ir-
reversible and insoluble aggregates on viscosity, but evidence now ex-
ists that particles increase the solution viscosity. Simulation and
experimental studies of stable and unstable (aggregated) colloidal sus-
pensions have demonstrated that aggregation increases the viscosity
of colloidal suspensions, particularly at low shear rates. Therefore, mea-
surements of low-shear viscosity on conventional rheometers can be of
great use in deducing particle effects on viscosity and has relevance to
formulation stability studies, which represent a zero-shear condition,
slow ﬂow in large pipes, and shipping of material [83]. The effect of par-
ticles on viscosity has been shown in a surfactant-free IgG1 solution
kept at storage conditions (2–8 °C) [1] and also in another surfactant-
laden IgG1 solution incubated at 40 °C for approximately 41 days
(Fig. 4) [84,85]. Both papers clearly document the presence of a yield
stress in these aggregating IgG1 solutions, and the increased viscosity
in these works agrees with the result originally reported by Patapoff
and Esue [86] that the solution viscosity of highly concentratedmAb so-
lutions increases due to the formation of insoluble aggregates. All these
workers measured ﬂow curves on their protein solutions, which hasFig. 4. The effects of sub-visible particles formed by prolonged thermal incubation on the
shear rate-dependent viscosity of a monoclonal antibody solution at 40 °C. Note that the
control (unheated) solution at the zero time point shows Newtonian response, which un-
dergoes a marked transition to non-Newtonian response, especially at low shear rates.
Eventually, a yield stress develops, and the inset shows the growth of the yield stress
with incubation time. These data highlight the important effects that SVPs have on solu-
tion viscosity, as well as the necessity of measuring viscosity vs. shear rate ﬂow curves.
Adapted from Castellanos et al., Soft Matter (2013) (Ref. [84]).facilitated a more complete understanding of the effects of particulates
on solution viscosity.
The rheology of the aggregating solution in Fig. 4 shows a transition
from Newtonian response in the monomeric/stable state to non-
Newtonian response as aggregation proceeds in a thermally incubated
environment, and a yield stress develops, though its origins are not
completely understood currently. The low shear rate upturn in the vis-
cosity is removed by ﬁltering the solution, and the low wavevector,
i.e., large real space length scale upturn in the scattering intensity in
SANS experiments also disappears upon ﬁltration [84,85]. This key re-
sult conﬁrms that fractal sub-micrometer particles, formed by Reaction
Limited-Aggregation (RLA) mechanism, drive the increase in the low
shear rate viscosity as well as the lowwavevector upturn in the scatter-
ing intensity of that aggregating antibody solution. The fractal dimen-
sion of the aggregates, inferred from scattering data, serves to verify
RLA as themechanism of aggregate growth, as is seen inmany other un-
stable colloidal suspensions. RLAhas been veriﬁed by static light scatter-
ing experiments [46] on other aggregating IgG1 systems too, thus
conﬁrming the agreement between light scattering andneutron scatter-
ing. The low shear rate viscosity of antibody solutions is thus a sensitive
indicator of particle formation and growth. The sensitivity of low shear
viscosity to the presence of particles underscores the importance of
measuring the ﬂow curve, especially the low shear rate response, of un-
stable antibody solutions over a broad shear rate range to clearly discern
the effects of aggregation on the solution viscosity. Aggregating protein
solutions are clearly non-Newtonian, while stable, i.e., mostly mono-
meric protein solutions are Newtonian (Fig. 4). Neither ultrasonic
rheometry at 10 MHz (107 s−1) [87] nor Dynamic Light Scattering ap-
proaches that rely on scattering from Polystyrene bead tracers [26,88]
would detect this aggregation-driven increase in viscosity at low shear
rates. However, particle-tracking, DiffusingWave Spectroscopy, andDy-
namic Light Scattering-based microrheology techniques using the ap-
proach of Mason and Weitz can allow one to measure the zero-shear
viscosity. Microrheology therefore has promise as an ancillary screening
technique for stability in protein formulations, if one carefully checks
the data for artifacts.
While single shear-rate/frequency measurements are advantageous
and indeed necessary for high throughput formulation screening in the
bio-pharma industry, full ﬂow curves can provide rich information to
supplement stability data and should bemeasured to understand stabil-
ity effects on viscosity and syringeability.
7.4. The effects of A/W, O/W and solid (S)/W interfaces on protein viscosity
and stability
We begin with a discussion of solid/water interfaces ﬁrst, as their
consequences are impactful and not generally appreciated by most
workers who study protein solution rheology. Critical evidence for the
effects of solid surfaces is abundant in the bio-process engineering liter-
ature. Proteins encounter shear ﬂow kinematics during manufacturing
unit operations, e.g. in mixing, and also during transfer/ﬁlling using a
pump, shipping and unit operations such as mixing. Recent work has
shed much-needed molecular light on the effects of the solid–liquid in-
terface during impeller-driven mixing [89]. As seen in Fig. 5, shear ﬂow
at high strain rates generated by an impeller's rotation leads to mono-
mer loss with simultaneous increase in the turbidity/opalescence of a
dilute surfactant-free IgG solution formulated in Phosphate Buffered Sa-
line at pH 7.4. The dominant factors found to affect the antibody stability
were pH, which controls net charge on the protein surface, and also the
surface roughness associated with the solid–liquid interface. These re-
sults point to the role of charge driven adsorption of antibody on the
solid–liquid interface in surfactant-free solutions. Moreover, the forma-
tion of sub-visible particles during ﬁlling with pumps is also marked
with a rise in turbidity [90]. Antibodies can also be unstable in the pres-
ence of ﬂow around surfaces made of common materials such as stain-
less steel and ceramics. These observations lead to the important
Fig. 5. The effects of shear strain rate generated in a custom-built mixing device on IgG
monomer concentration and solution at 350 nm.Monomer loss is accompanied by growth
in solution turbidity opalescence during shear, both following exponential rate laws.
Adapted from Biddlecombe et al., Biotechnology Progress (2013) (Ref. [89]).
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be assumed to be benign to proteins.
In addition to consequences for unit operations, interfacial adsorp-
tion poses non-negligible consequences for rheometric measurements,
as adsorption results in partial unfolding and hydrophobically-driven
aggregation of protein molecules that create a ﬁlm. As an illustration,
one can quantitatively connect the average aggregate size and concen-
tration with a simple thought experiment for the case of particles
forming via a “shedding” process from the air–water interface, as has
been suggested based on experiments with antibody solutions [51].
Surface-adsorbed ﬁlms are viscoelastic and respond accordingly to in-
terfacial (two dimensional) shear and dilatation (changes in surface
area). In a recent report, Sharma et al. [91] have traced the existence
of a bulk shear yield stress in protein solutions solely to the viscoelastic
ﬁlm formed by adsorption at the A/W interface. They have also nicely
shown that the yielding in dilute protein solutions, as measured by ro-
tational rheometry, is due to the torque contribution of the adsorbed
protein ﬁlm at the A/W interface. A rheometer cannot identify the
source from which the generated torque emanates. Both the bulk
shear of the protein solution and the adsorbed protein layer at the A/
W interface can contribute to the measured torque. The reader should
note that carefully chosen measurement geometries can mitigate the
surface contribution, and provide robust measurements for protein so-
lutions, even surfactant-free ones. Moreover, it is now also known that
particles can also cause non-Newtonian shear yielding behavior [84].
The rheology of concentrated protein solutions is manifestly non-
Newtonian, and this non-linear response in the form of liquid-like
shear thinning or solid-like shear yielding should be appropriately
accounted for in the treatment of rheometry data.
7.5. Experimental data vs. theoretical models for protein solution viscosity
There are currently no protein-speciﬁc molecular theories for the
composition dependence of viscosity of stable (monomeric) proteins
in solution. Theoretical models for the viscoelasticity of unstable/aggre-
gating protein solutions are understandably unavailable, given the com-
plex challenge they pose in terms of concurrently modeling the
hydrodynamic response of concentrated protein solutions comprising
soluble monomers and aggregates as well as insoluble aggregates and
SVPs. Monomer–monomer and monomer–aggregate interactions
would also need to be accounted for in these concentrated systems.
The rheology of these irreversibly aggregating systems is complicated
also because they are inherently non-equilibriumsystems,whose rheol-
ogy reﬂects the time-dependent evolution of the morphology created
by irreversible protein aggregation and the precipitation of SVPs.While colloidal models such as the Russell–Saville–Schowalter
model [92] and the Krieger–Dougherty model [93] and even entangle-
ment scaling models [94] have been applied to model the composi-
tion dependent viscosity of protein and antibody solutions, they
possess signiﬁcant limitations. Application of colloidal models com-
monly assumes one-to-one equivalence between proteins and
charged hard-sphere colloids, which have uniform surface charge
distribution. This assumption fails for globular proteins like BSA
[95] and also for multi-domain proteins such as IgGs [96]. The impli-
cations of such non-uniform charge distribution on RSA in IgGs are
not negligible, and colloidal models cannot capture this complexity.
Spherical models simply do not hold for the solution viscosity of
globular proteins such as BSA and multi-domain proteins have
even greater deviations from spheres assumed to have homoge-
neous surface charge distribution. All proteins in buffered solutions
have a surface charge distribution that changes with pH. Even at its
iso-electric point, pI, BSA possesses patches of negative and positive
charges on its surface, while maintaining zero net charge. Charge–
charge and charge-induced dipole interactions would still persist in
protein solutions at the pI. Moreover, proteins also possess a hydra-
tion shell [97], which signiﬁcantly alter their solution hydrodynam-
ics, as reviewed by Halle in [98] and also their solution rheology,
viz. the composition dependence of solution viscosity [95]. To test
the applicability of colloidal rheology models to protein solutions,
the volume fraction must be calculated based on protein composi-
tion. If the hydration shell is ignored in the calculation of the protein
volume fraction, then one reaches the apparent, though erroneous,
conclusion that colloidal models quantitatively predict/correlate
the viscosity of protein solutions [91]. Charge and hydration are
both fundamental to protein solution rheology.
In addition to differences in charge and hydration, analogies be-
tween proteins and colloids can be called into question due to a priori
assumption of shape for protein molecules, regardless of whether they
are in dilute or concentrated solutions. BSA, which has been assumed
to be a hard sphere [97] for the treatment of small-angle X-ray scatter-
ing data from its crowded solutions, is neither a hard sphere in the hy-
drodynamic sense [95], nor in the thermodynamic sense [99]. Proteins
are macromolecules, whose dynamic conformations are universally ac-
cepted. There is now evidence from near UV CD for changes in tertiary
structure in crowded BSA solutions [99] and also in crowded IgG1 solu-
tions fromnearUVCD, AUCand SANS. At high concentrationsmolecules
can sometimes adopt less compact conformations, which experience
larger hydrodynamic friction/drag and thus experience higher viscosity.
While changes in friction coefﬁcient of a hard sphere can be captured by
changing the charge and charge distribution on its surface, these hard
sphere models do not account for charge effects and focus only on ex-
cluded volume interactions. While excluded volume interactions are
undoubtedly non-negligible in crowded protein solutions, they are by
no means the sole determinant of protein solution viscosity. We there-
fore do not consider empirical quasi-spherical hard spheremodels [100]
for the protein concentration dependence of solution viscosity for dis-
cussion here. It is our assessment that a priori assumptions of protein
shape and conformation in concentrated solutions have hampered
progress in this ﬁeld.
In contrast to quasi-spherical hard-sphere models, recent work has
extended a scaling theory for the viscosity of semi-dilute polymer solu-
tions [94] to the viscosity of high concentration antibody solutions.
While the approach succeeds in ﬁtting the data, the scaling approach as-
sumes that antibodymolecules form an entanglement network. To date,
published literature reports have not found evidence of an entangle-
ment network, which is typically manifested by a plateau in the shear
storagemodulus,G′. While thismodel succeeds in ﬁtting the data, albeit
with a signiﬁcant number of adjustable parameters, this scaling ap-
proach assumes that antibody molecules form an entanglement
network. However, no information is available in Ref. [94] that shows
the existence of an entanglement network, as evidenced by a plateau
448 S. Amin et al. / Current Opinion in Colloid & Interface Science 19 (2014) 438–449in G′. The readers should note, however, that the assumption of
an entanglement network can be considered to be simply a usefulmath-
ematical construct to facilitate comparison with experimental data, and
it provides a simple means to relate the size of a transient network to
the timescale for rearrangement of that network.
In summary, the ﬁeld of protein solution rheology is wide open for
new molecular theories to be proposed. Proteins are complex macro-
molecules, whose solution viscosity depends of many factors, viz.,
molarmass (inﬂuenced by RSA), charge and charge distribution, hydra-
tion, conformation, protein–protein interactions etc. The authors hope
that the coming years herald signiﬁcant new advances in this ﬁeld.
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